Scientists reorganized their lives to move the world toward safety
En un año que pareció comprimir décadas de historia en doce meses, la revista Science reconoció las vacunas contra la COVID-19 como el mayor logro científico de 2020, no como un milagro repentino, sino como la culminación de generaciones de investigación silenciosa que esperaba su momento. Lo que el mundo vivió como una carrera frenética fue, en realidad, la cosecha de semillas plantadas años antes: una plataforma de ARN mensajero desarrollada en 2005, empresas fundadas sobre esa promesa, y científicos que reorganizaron sus vidas enteras alrededor de un propósito común. La humanidad no venció al virus por suerte, sino porque, sin saberlo, llevaba años preparándose.
- Un virus desconocido pasó de secuencia genética publicada a emergencia global en menos de tres semanas, dejando al mundo sin tiempo para asimilar lo que ocurría.
- Mientras los gobiernos dudaban y los hospitales colapsaban, equipos científicos trabajaban jornadas de dieciocho horas convencidos de que un año era un plazo imposible.
- El 9 de noviembre, Pfizer y BioNTech anunciaron una eficacia del 95%; una semana después, Moderna igualó ese resultado, pulverizando el récord anterior de cinco años para el desarrollo de una vacuna.
- Detrás del aparente milagro había décadas de trabajo invisible: el descubrimiento de Katalin Karikó en 2005 sobre el ARN mensajero fue la llave que abrió la cerradura cuando el mundo más lo necesitaba.
- Las vacunas de Oxford y AstraZeneca, más baratas y fáciles de almacenar, apuntaban a cerrar la brecha entre países ricos y pobres, convirtiendo un logro científico en una posibilidad global.
A principios de enero de 2020, cuando el mundo apenas comenzaba a escuchar la palabra coronavirus, los científicos ya estaban en movimiento. El 10 de enero, investigadores chinos publicaron la secuencia genética del nuevo virus. Tres días después, antes de que la OMS declarara ninguna emergencia, los NIH y Moderna ya habían diseñado una vacuna. La velocidad era tan desconcertante que parecía violar las leyes del tiempo científico.
Lo que siguió fue una escalada vertiginosa: Wuhan confinada, Italia en llamas, España en estado de alarma, y Moderna iniciando ensayos en humanos el 16 de marzo. Juan Andrés, director técnico de la compañía, declaró ese mes que no creía posible tener una vacuna en menos de un año. Su equipo trabajaba dieciocho horas diarias. Se equivocó en el plazo. El 9 de noviembre, Pfizer y BioNTech anunciaron una eficacia cercana al 95%; Moderna la igualó una semana después. Ambas habían superado el récord anterior —la vacuna contra el ébola Ervebo, que tardó cinco años en aprobarse.
Pero el milagro tenía raíces profundas. En 2005, la bioquímica húngara Katalin Karikó y el inmunólogo Drew Weissman publicaron un método para modificar el ARN mensajero de forma segura. Ese hallazgo esperó años en la literatura científica hasta que Derrick Rossi fundó Moderna en 2010 y Ugur Sahin y Özlem Türeci crearon BioNTech en Alemania, incorporando a la propia Karikó a su equipo en 2013. Cuando llegó el coronavirus, las plataformas estaban listas. No hubo que inventar nada desde cero: solo insertar las instrucciones genéticas de un virus nuevo.
Holden Thorp, editor de Science, reconoció en su editorial que la ciencia también tropezó: la respuesta tardía sobre las mascarillas, el reconocimiento lento de la transmisión aérea, irregularidades en algunos estudios. Pero subrayó lo que importaba: miles de científicos habían reorganizado sus vidas alrededor de un único propósito. Para diciembre de 2020, lo imposible se había vuelto rutina. El virus que llegó de la nada en enero encontró su respuesta antes de que terminara el año, no por accidente, sino por el peso acumulado de décadas de conocimiento que esperaba, sin saberlo, este momento exacto.
In early January 2020, when most of the world had barely registered that a new virus existed, the scientific machinery was already moving. Chinese researchers confirmed a novel coronavirus on January 10 and published its genetic sequence within hours. By January 13—before the World Health Organization had even declared an international emergency—scientists at the U.S. National Institutes of Health and the company Moderna had already designed a vaccine. The speed was so disorienting that it seemed to violate the laws of how science actually works. Yet on December 17, 2020, the journal Science named COVID-19 vaccines its breakthrough of the year, a recognition that felt less like an award and more like documentation of something almost impossible that had actually happened.
The timeline that year was a blur of escalation. China's government initially denied human-to-human transmission on January 12, then reversed course eight days later. Wuhan locked down. The WHO declared a global emergency on January 30. Italy erupted in cases by late February. Spain imposed a state of alarm on March 14. And on March 16, Moderna began human trials of its experimental vaccine—all while the world was still reeling from the shock of what was happening. Juan Andrés, Moderna's technical director, told a Spanish newspaper on March 21 that he didn't believe a vaccine could be ready in less than a year. His team was working eighteen-hour days, he said, stopping only to sleep. He was wrong about the timeline, though not about the intensity. On November 9, Pfizer and BioNTech announced their vaccine had nearly 95 percent efficacy. A week later, Moderna matched that result. Both companies had shattered the previous record—the Ervebo vaccine for Ebola, which took five years from human trials to approval in 2019.
But this wasn't a sudden miracle. Holden Thorp, the editor of Science, emphasized that these vaccines were the product of decades of foundational work. The crucial breakthrough came in 2005, when Hungarian biochemist Katalin Karikó and American immunologist Drew Weissman published a method for safely modifying messenger RNA so it could be used in vaccines without triggering dangerous immune reactions. That discovery sat in the scientific literature for years, waiting. In 2010, Canadian biologist Derrick Rossi co-founded Moderna on the strength of that knowledge. In Germany, two scientists of Turkish origin, Ugur Sahin and Özlem Türeci, started BioNTech and brought Karikó herself onto their team in 2013 to develop RNA-based medicines. When the coronavirus arrived, both companies had their platforms ready. They didn't need to invent the wheel. They just needed to swap in the genetic instructions for a new virus.
The technology itself was elegant: a strand of genetic code that told human cells to manufacture harmless viral proteins, training the immune system without any actual infection. Both leading vaccines used this same approach, which meant they could be developed in parallel, tested simultaneously, and deployed together. Thorp acknowledged in his editorial that science had stumbled along the way—the initial dismissal of masks, the slow recognition that the virus traveled through the air, irregularities in some studies. But he argued that what mattered now was what had gone right: scientists had reorganized their lives around a single purpose, to move the world toward safety.
Other vaccines were close behind. Oxford University and AstraZeneca had a candidate in late-stage trials that promised to be cheaper and easier to store than the mRNA vaccines, a crucial advantage for poorer countries where refrigeration infrastructure couldn't support the extreme cold requirements of Pfizer and Moderna. The race wasn't over. But by December 2020, the impossible had become routine. The virus that had seemed to arrive from nowhere in January had met its match by year's end, not through luck or accident, but through the accumulated knowledge of scientists who had spent years preparing for a crisis they couldn't have predicted, only imagined.
Citas Notables
The dedication to the pursuit of truth, to improving the human condition, and to documenting everything for posterity is common across all areas of science— Holden Thorp, editor of Science magazine
We're working 18 hours a day. We stop only to sleep— Juan Andrés, technical director of Moderna, March 2020
La Conversación del Hearth Otra perspectiva de la historia
Why does Science magazine calling this a breakthrough matter? Isn't that just what magazines do—celebrate good news?
Because Science is where scientists read about what other scientists think is actually important. It's not a popularity contest. When they name something breakthrough of the year, they're saying this is what moved the needle on human knowledge and capability. In this case, they're saying the speed itself is the story—not just that vaccines work, but that we figured out how to make them work in months instead of years.
But you said it was built on decades of work. So wasn't it really fast, or was it slow?
Both. The actual development—from genetic sequence to efficacy data—was shockingly fast. But that was only possible because Karikó and Weissman solved a fundamental problem fifteen years earlier, and companies had spent a decade building platforms on top of that. The speed was real. The foundation was deeper.
The article mentions that Moderna's director said a year was the earliest possible timeline, and he was wrong. What changed?
He wasn't wrong about what was possible in theory. He was wrong about what was possible when every regulatory barrier got cleared, when funding appeared instantly, when thousands of people stopped doing other things and focused on one problem. The science didn't change. The resources and urgency did.
Why does it matter that Oxford and AstraZeneca's vaccine is cheaper and easier to store?
Because the Pfizer and Moderna vaccines need to be kept at minus 70 degrees Celsius. Most of the world doesn't have freezers like that. If you can only vaccinate wealthy countries, you haven't solved the pandemic—you've just made it someone else's problem. AstraZeneca's vaccine could actually reach the places that needed it most.
Thorp mentions that science made mistakes—about masks, about airborne transmission. Does that undercut the celebration?
He's saying no, not really. He's saying yes, there were failures, but the larger story is that scientists cared enough to keep working, to correct course, to prioritize the problem over being right. That's what he thinks is worth celebrating.